MD Anderson announces new leadership...
The University of Texas MD Anderson Cancer Center today announced a new leadership structure designed to enhance teamwork and collaborative decision-making. It is effective today.
The new structure is based on advancing institutional priorities of financial sustainability, connecting the MD Anderson community to its decision-making process and improved teamwork. Outcomes will include improved clarity in decision-making, increased...
MD Anderson UTHealth Graduate School receives $10.5 million gift
Just as he has changed the lives of people suffering from a devastating genetic disease, molecular endocrinologist John J. Kopchick,...
Making Cancer History® Seminar returns to Aspen
The University of Texas MD Anderson Cancer Center plans its 19th annual Making Cancer History® seminar in Aspen, free and open to the...
MD Anderson and Convergent R.N.R. Ltd....
The University of Texas MD Anderson Cancer Center and Convergent R.N.R. Ltd. (CRnR) today announced a collaboration to further develop new radiation technology aimed at reducing side effects of standard radiation including unwanted radiation to healthy tissue.
The alliance will study the feasibility of using CRnR’s converging x-ray lens technology as an effective radiotherapy and radiosurgery option. MD Anderson will develop...
Innovative therapy strategy for pancreatic cancer uses...
Genetic manipulation of exosomes, virus-sized particles released by all cells, may offer a new therapeutic approach to treating...
MD Anderson and Hitachi to collaborate in research for...
The University of Texas MD Anderson Cancer Center and Hitachi Healthcare Americas Corporation, have today announced that they have...
Higher gut bacteria diversity tied to slower metastatic...
The blend of bacteria in the digestive tract of metastatic melanoma patients is associated with disease progression or delay in...
Two combination therapies shrink melanoma brain metastases...
High response rates to a pair of combination therapies point to potentially new options for a group of metastatic melanoma patients...